An Update to the Pilot Study of 177Lu-PSMA in Low Volume Hormone-Sensitive Prostate Cancer

Bastiaan M. Privé; Constantijn H.J. Muselaers; Inge M. van Oort; Marcel J.R. Janssen; Steffie M.B. Peters; Willemijn A.M. van Gemert; Maike J.M. Uijen; Melline M.G. Schilham; J. P.Michiel Sedelaar; Harm Westdorp; Niven Mehra; Martin Gotthardt; Jelle O. Barentsz; Winald R. Gerritsen; J. Alfred Witjes; James Nagarajah

doi:10.3389/fnume.2022.863101

An Update to the Pilot Study of ¹⁷⁷Lu-PSMA in Low Volume Hormone-Sensitive Prostate Cancer

Bastiaan M. Privé^*, Constantijn H.J. Muselaers, Inge M. van Oort, Marcel J.R. Janssen, Steffie M.B. Peters, Willemijn A.M. van Gemert, Maike J.M. Uijen, Melline M.G. Schilham, J. P.Michiel Sedelaar, Harm Westdorp, Niven Mehra, Martin Gotthardt, Jelle O. Barentsz, Winald R. Gerritsen, J. Alfred Witjes, James Nagarajah

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

5 Citations (Scopus)

Abstract

¹⁷⁷Lu-PSMA-617 radioligand therapy is a novel treatment for end-stage prostate cancer, which could also be applied to patients with hormone-sensitive prostate cancer with high expression levels of prostate-specific membrane antigen (PSMA). In this perspective, we review the recent results of toxicity, radiation doses, and treatment effect of ¹⁷⁷Lu-PSMA in patients with low volume metastatic hormone-sensitive prostate cancer. Moreover, we present long-term follow-up data, such as toxicity and time without androgen deprivation therapy (ADT), of the patients who participated in this trial. Overall, ¹⁷⁷Lu-PSMA appeared to be a feasible and safe treatment modality in this setting, as well as in long-term follow-up. We observed that men with a prostate-specific antigen (PSA) response of more than 50% seemed to especially benefit from this therapy by postponing ADT and thus preserving the quality of life.

Original language	English
Article number	863101
Journal	Frontiers in Nuclear Medicine
Volume	2
DOIs	https://doi.org/10.3389/fnume.2022.863101
Publication status	Published - 3 May 2022
Externally published	Yes

Bibliographical note

Publisher Copyright:
Copyright © 2022 Privé, Muselaers, van Oort, Janssen, Peters, van Gemert, Uijen, Schilham, Sedelaar, Westdorp, Mehra, Gotthardt, Barentsz, Gerritsen, Witjes and Nagarajah.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3389/fnume.2022.863101

Cite this

Privé, B. M., Muselaers, C. H. J., van Oort, I. M., Janssen, M. J. R., Peters, S. M. B., van Gemert, W. A. M., Uijen, M. J. M., Schilham, M. M. G., Sedelaar, J. P. M., Westdorp, H., Mehra, N., Gotthardt, M., Barentsz, J. O., Gerritsen, W. R., Witjes, J. A., & Nagarajah, J. (2022). An Update to the Pilot Study of ¹⁷⁷Lu-PSMA in Low Volume Hormone-Sensitive Prostate Cancer. Frontiers in Nuclear Medicine, 2, Article 863101. https://doi.org/10.3389/fnume.2022.863101

@article{d29f673a1c8546de95f38cd876a3f889,

title = "An Update to the Pilot Study of 177Lu-PSMA in Low Volume Hormone-Sensitive Prostate Cancer",

abstract = "177Lu-PSMA-617 radioligand therapy is a novel treatment for end-stage prostate cancer, which could also be applied to patients with hormone-sensitive prostate cancer with high expression levels of prostate-specific membrane antigen (PSMA). In this perspective, we review the recent results of toxicity, radiation doses, and treatment effect of 177Lu-PSMA in patients with low volume metastatic hormone-sensitive prostate cancer. Moreover, we present long-term follow-up data, such as toxicity and time without androgen deprivation therapy (ADT), of the patients who participated in this trial. Overall, 177Lu-PSMA appeared to be a feasible and safe treatment modality in this setting, as well as in long-term follow-up. We observed that men with a prostate-specific antigen (PSA) response of more than 50% seemed to especially benefit from this therapy by postponing ADT and thus preserving the quality of life.",

author = "Priv{\'e}, {Bastiaan M.} and Muselaers, {Constantijn H.J.} and {van Oort}, {Inge M.} and Janssen, {Marcel J.R.} and Peters, {Steffie M.B.} and {van Gemert}, {Willemijn A.M.} and Uijen, {Maike J.M.} and Schilham, {Melline M.G.} and Sedelaar, {J. P.Michiel} and Harm Westdorp and Niven Mehra and Martin Gotthardt and Barentsz, {Jelle O.} and Gerritsen, {Winald R.} and Witjes, {J. Alfred} and James Nagarajah",

note = "Publisher Copyright: Copyright {\textcopyright} 2022 Priv{\'e}, Muselaers, van Oort, Janssen, Peters, van Gemert, Uijen, Schilham, Sedelaar, Westdorp, Mehra, Gotthardt, Barentsz, Gerritsen, Witjes and Nagarajah.",

year = "2022",

month = may,

day = "3",

doi = "10.3389/fnume.2022.863101",

language = "English",

volume = "2",

journal = "Frontiers in Nuclear Medicine",

issn = "2673-8880",

publisher = "Frontiers Media SA",

}

Privé, BM, Muselaers, CHJ, van Oort, IM, Janssen, MJR, Peters, SMB, van Gemert, WAM, Uijen, MJM, Schilham, MMG, Sedelaar, JPM, Westdorp, H, Mehra, N, Gotthardt, M, Barentsz, JO, Gerritsen, WR, Witjes, JA & Nagarajah, J 2022, 'An Update to the Pilot Study of ¹⁷⁷Lu-PSMA in Low Volume Hormone-Sensitive Prostate Cancer', Frontiers in Nuclear Medicine, vol. 2, 863101. https://doi.org/10.3389/fnume.2022.863101

TY - JOUR

T1 - An Update to the Pilot Study of 177Lu-PSMA in Low Volume Hormone-Sensitive Prostate Cancer

AU - Privé, Bastiaan M.

AU - Muselaers, Constantijn H.J.

AU - van Oort, Inge M.

AU - Janssen, Marcel J.R.

AU - Peters, Steffie M.B.

AU - van Gemert, Willemijn A.M.

AU - Uijen, Maike J.M.

AU - Schilham, Melline M.G.

AU - Sedelaar, J. P.Michiel

AU - Westdorp, Harm

AU - Mehra, Niven

AU - Gotthardt, Martin

AU - Barentsz, Jelle O.

AU - Gerritsen, Winald R.

AU - Witjes, J. Alfred

AU - Nagarajah, James

PY - 2022/5/3

Y1 - 2022/5/3

N2 - 177Lu-PSMA-617 radioligand therapy is a novel treatment for end-stage prostate cancer, which could also be applied to patients with hormone-sensitive prostate cancer with high expression levels of prostate-specific membrane antigen (PSMA). In this perspective, we review the recent results of toxicity, radiation doses, and treatment effect of 177Lu-PSMA in patients with low volume metastatic hormone-sensitive prostate cancer. Moreover, we present long-term follow-up data, such as toxicity and time without androgen deprivation therapy (ADT), of the patients who participated in this trial. Overall, 177Lu-PSMA appeared to be a feasible and safe treatment modality in this setting, as well as in long-term follow-up. We observed that men with a prostate-specific antigen (PSA) response of more than 50% seemed to especially benefit from this therapy by postponing ADT and thus preserving the quality of life.

AB - 177Lu-PSMA-617 radioligand therapy is a novel treatment for end-stage prostate cancer, which could also be applied to patients with hormone-sensitive prostate cancer with high expression levels of prostate-specific membrane antigen (PSMA). In this perspective, we review the recent results of toxicity, radiation doses, and treatment effect of 177Lu-PSMA in patients with low volume metastatic hormone-sensitive prostate cancer. Moreover, we present long-term follow-up data, such as toxicity and time without androgen deprivation therapy (ADT), of the patients who participated in this trial. Overall, 177Lu-PSMA appeared to be a feasible and safe treatment modality in this setting, as well as in long-term follow-up. We observed that men with a prostate-specific antigen (PSA) response of more than 50% seemed to especially benefit from this therapy by postponing ADT and thus preserving the quality of life.

UR - http://www.scopus.com/inward/record.url?scp=85160379476&partnerID=8YFLogxK

U2 - 10.3389/fnume.2022.863101

DO - 10.3389/fnume.2022.863101

M3 - Article

AN - SCOPUS:85160379476

SN - 2673-8880

VL - 2

JO - Frontiers in Nuclear Medicine

JF - Frontiers in Nuclear Medicine

M1 - 863101

ER -